Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab

BACKGROUND: Although PD-1 antibodies (PD1 Ab) are the standard of care for advanced non-small-cell lung cancer (ansclc), most patients will progress. We compared survival outcomes for patients with ansclc who received systemic therapy (st) after progression and for those who did not. Additionally, c...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Curr Oncol
Main Authors: Freeman, A.T., Lesperance, M., Wai, E.S., Croteau, N.S., Fiorino, L., Geller, G., Brooks, E.G., Poonja, Z., Fenton, D., Irons, S., Ksienski, D.
Formato: Artigo
Idioma:Inglês
Publicado: Multimed Inc. 2020
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7253749/
https://ncbi.nlm.nih.gov/pubmed/32489249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.27.5495
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares